People · Operator
Named in public records as an officer, director or promoter · active 2010–2011 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aerovance Inc | — | Biotechnology | Series B | $22.5M | $19.8M | 2010 |
Alain G. Schreiber at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alain G. Schreiber on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Walker | 1 | 17 |
| Mark Perry | 1 | 6 |
| Farah Champsi | 1 | 5 |
| Douglas E. Williams | 1 | 4 |
| Nick Galakatos | 1 | 3 |
| Alain Schreiber | 1 | 3 |
| Nicholas G. Galakatos | 1 | 2 |
| ANTHONY RIMAC | 1 | 2 |
| Ann Hanham | 1 | 1 |
| Robert Kuhn | 1 | 1 |
| David Happel | 1 | 1 |
| John G. Walker | 1 | 1 |
| David A. Happel | 1 | 1 |
| Anthony E. Rimac | 1 | 1 |
| Robert W. Kuhn | 1 | 1 |
| Ann G. Hanham | 1 | 1 |
| Tunde W. Otulana | 1 | 1 |
| Mark E. Perry | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.